TTC9C Activators

TTC9C can initiate a cascade of intracellular events that result in the protein's activation. Forskolin is known for its direct stimulation of adenylyl cyclase, which catalyzes the conversion of ATP to cAMP. Elevated cAMP levels lead to the activation of protein kinase A (PKA), a pivotal enzyme in phosphorylation processes. Once activated, PKA can phosphorylate TTC9C, thereby modulating its activity. Similarly, IBMX and Rolipram exert their effects by inhibiting phosphodiesterases, enzymes responsible for cAMP breakdown. This inhibition maintains high cAMP levels within the cell, thus sustaining PKA activity and fostering a conducive environment for the phosphorylation of TTC9C.

Epinephrine and Isoproterenol engage with adrenergic receptors and are known to enhance the production of cAMP via adenylyl cyclase activation. This increase in cAMP levels results in the activation of PKA, which can then target TTC9C. Additionally, N6-Benzoyl-cAMP, a cAMP analog, directly activates PKA. PGE1, through its action on G-protein coupled receptors, also contributes to the rise in cAMP and subsequent PKA activation. PKA, once active, phosphorylates TTC9C, modulating its function. L-858051, by directly activating adenylyl cyclase, contributes to the same outcome, enhancing the phosphorylation potential of TTC9C. Moreover, agents like Glucagon and Terbutaline elevate cAMP levels through their receptor-mediated effects, which in turn activate PKA and promote the phosphorylation of TTC9C. Dibutyryl-cAMP, bypassing cellular control mechanisms to directly activate PKA, and Anagrelide, through its inhibition of PDE3, both sustain elevated levels of cAMP and facilitate the activation of PKA. This consistent activation of PKA across different pathways underscores a common endpoint: the phosphorylation and consequent activation of TTC9C.